Cryoport Launches its IntegriCell™ Cryopreservation Solution with Opening of New Facility at its Houston Campus
Cryoport, Inc. (NASDAQ: CYRX) has launched its IntegriCell™ cryopreservation services solution with the opening of a new facility at its Houston campus. The state-of-the-art facility is dedicated to the standardized cryopreservation of leukapheresis material, integrating with Cryoport's end-to-end global temperature-controlled supply chain platform to support cell-based therapies.
The IntegriCell platform aims to enhance cell therapy manufacturing efficiency and flexibility, ensuring safety, quality, and product stability. The Houston site also supports GMP-compliant biostorage and a full suite of bioservices, including secondary packaging, labeling, kit production, and logistics capabilities.
Cryoport's CEO, Jerrell Shelton, stated that the new facility expands their presence in Houston and is a significant milestone in providing integrated supply chain solutions for cell and gene therapies. The company believes IntegriCell will offer the industry's first complete solution for optimized cellular starting materials, potentially accelerating treatment delivery and opening new revenue streams.
Cryoport, Inc. (NASDAQ: CYRX) ha lanciato la sua soluzione di servizi di crioconservazione IntegriCell™ con l'apertura di una nuova struttura nel suo campus di Houston. La struttura all'avanguardia è dedicata alla crioconservazione standardizzata del materiale da leucafere, integrandosi con la piattaforma globale di supply chain a temperatura controllata di Cryoport per supportare le terapie cellulari.
La piattaforma IntegriCell mira a migliorare l'efficienza e la flessibilità nella produzione di terapie cellulari, garantendo sicurezza, qualità e stabilità del prodotto. Il sito di Houston supporta anche biostorage conforme alle normative GMP e un'ampia gamma di bioservizi, inclusi imballaggio secondario, etichettatura, produzione di kit e capacità logistiche.
Il CEO di Cryoport, Jerrell Shelton, ha dichiarato che la nuova struttura espande la loro presenza a Houston ed è una tappa significativa nella fornitura di soluzioni integrate della catena di approvvigionamento per terapie cellulari e geniche. L'azienda crede che IntegriCell offrirà la prima soluzione completa del settore per materiali cellulari ottimizzati, potenzialmente accelarando la consegna dei trattamenti e aprendo nuovi flussi di entrate.
Cryoport, Inc. (NASDAQ: CYRX) ha lanzado su solución de servicios de crioconservación IntegriCell™ con la apertura de una nueva instalación en su campus de Houston. La instalación de última generación está dedicada a la crioconservación estandarizada del material de leucaféresis, integrándose con la plataforma de cadena de suministro global a temperatura controlada de Cryoport para apoyar las terapias basadas en células.
La plataforma IntegriCell tiene como objetivo mejorar la eficiencia y flexibilidad en la fabricación de terapias celulares, garantizando seguridad, calidad y estabilidad del producto. El sitio de Houston también apoya biocustodia conforme a GMP y una gama completa de bioservicios, que incluyen embalaje secundario, etiquetado, producción de kits y capacidades logísticas.
El CEO de Cryoport, Jerrell Shelton, declaró que la nueva instalación expande su presencia en Houston y es un hito significativo en la provisión de soluciones integradas de cadena de suministro para terapias celulares y génicas. La empresa cree que IntegriCell ofrecerá la primera solución completa de la industria para materiales celulares optimizados, lo que podría acelerar la entrega del tratamiento y abrir nuevas fuentes de ingresos.
Cryoport, Inc. (NASDAQ: CYRX)가 휴스턴 캠퍼스에 새로운 시설을 열며 IntegriCell™ 크라이오보존 서비스 솔루션을 출시했습니다. 최첨단 시설은 백혈구 채혈 재료의 표준화된 크라이오보존에 전념하고 있으며, Cryoport의 엔드 투 엔드 글로벌 온도 제어 공급망 플랫폼과 통합되어 세포 기반 치료를 지원합니다.
IntegriCell 플랫폼은 세포 치료 제조 효율성과 유연성을 향상시키고, 안전성, 품질 및 제품 안정성을 보장하는 것을 목표로 하고 있습니다. 휴스턴 사이트는 GMP 준수 바이오 저장 및 전체 바이오 서비스 솔루션을 지원하며, 이에는 2차 포장, 라벨링, 키트 생산 및 물류 기능이 포함됩니다.
Cryoport의 CEO Jerrell Shelton은 새로운 시설이 휴스턴에서의 존재를 확장하고 세포 및 유전자 치료를 위한 통합 공급망 솔루션을 제공하는 중요한 이정표라고 밝혔습니다. 회사는 IntegriCell이 최적화된 세포 시작 재료를 위한 업계 최초의 완전한 솔루션을 제공하여 치료 제공을 가속화하고 새로운 수익 흐름을 열 수 있다고 믿고 있습니다.
Cryoport, Inc. (NASDAQ: CYRX) a lancé sa solution de services de cryoconservation IntegriCell™ avec l'ouverture d'une nouvelle installation sur son campus de Houston. Cette installation à la pointe de la technologie est dédiée à la cryoconservation standardisée des matériaux de leucaphérèse, s'intégrant à la plateforme mondiale de chaîne d'approvisionnement à température contrôlée de Cryoport pour soutenir les thérapies cellulaires.
La plateforme IntegriCell vise à améliorer l'efficacité et la flexibilité de la fabrication de thérapies cellulaires, garantissant la sécurité, la qualité et la stabilité du produit. Le site de Houston prend également en charge la bioconservation conforme aux GMP et une gamme complète de bioservices, y compris l'emballage secondaire, l'étiquetage, la production de kits et des capacités logistiques.
Le PDG de Cryoport, Jerrell Shelton, a déclaré que la nouvelle installation élargit leur présence à Houston et constitue une étape importante dans la fourniture de solutions intégrées de chaîne d'approvisionnement pour les thérapies cellulaires et géniques. L'entreprise croit qu'IntegriCell offrira la première solution complète de l'industrie pour des matériaux cellulaires optimisés, accélérant potentiellement la livraison des traitements et ouvrant de nouvelles sources de revenus.
Cryoport, Inc. (NASDAQ: CYRX) hat seine Lösung für Kryokonservierungsdienstleistungen IntegriCell™ mit der Eröffnung einer neuen Einrichtung auf seinem Campus in Houston gestartet. Die hochmoderne Einrichtung ist der standardisierten Kryokonservierung von Leukoferese-Material gewidmet und integriert sich in Cryoports End-to-End-Plattform für temperatureingestellte globale Lieferketten, um zellbasierte Therapien zu unterstützen.
Die IntegriCell-Plattform zielt darauf ab, die Effizienz und Flexibilität der Zelltherapiefertigung zu verbessern und dabei Sicherheit, Qualität und Produktstabilität zu gewährleisten. Der Standort Houston unterstützt auch GMP-konforme Biolagerung und ein vollständiges Spektrum an Bioservices, einschließlich sekundärer Verpackung, Etikettierung, Kit-Produktion und Logistikfähigkeiten.
Der CEO von Cryoport, Jerrell Shelton, erklärte, dass die neue Einrichtung ihre Präsenz in Houston erweitert und einen bedeutenden Meilenstein bei der Bereitstellung integrierter Lieferkettensolutions für Zell- und Gentherapien darstellt. Das Unternehmen glaubt, dass IntegriCell die erste umfassende Lösung der Branche für optimierte zelluläre Ausgangsmaterialien bieten wird, was die Behandlungslieferung beschleunigen und neue Einnahmequellen eröffnen könnte.
- Launch of IntegriCell™ cryopreservation services solution
- Opening of new state-of-the-art facility in Houston
- Potential for new revenue streams from new and existing customers
- Integration with Cryoport's end-to-end global temperature-controlled supply chain platform
- Expansion of services including GMP-compliant biostorage and bioservices
- None.
Insights
The launch of Cryoport's IntegriCell™ cryopreservation solution and the opening of a new facility in Houston represent a significant expansion of the company's service offerings. This development has the potential to positively impact Cryoport's revenue streams by tapping into the growing cell therapy market.
Key points to consider:
- The IntegriCell platform aims to enhance efficiency in cell therapy manufacturing, which could attract new customers and strengthen relationships with existing ones.
- By offering standardized bioprocessing and cryopreservation services, Cryoport is positioning itself as a one-stop solution provider in the cell therapy supply chain.
- The integration of multiple services at the Houston campus (cryopreservation, logistics, biostorage and fulfillment) could lead to operational synergies and cost efficiencies.
While the immediate financial impact may be , this expansion aligns with Cryoport's long-term growth strategy in the rapidly evolving cell and gene therapy market. Investors should monitor future earnings reports for evidence of revenue growth attributed to this new service offering.
The launch of IntegriCell™ and the new Houston facility marks a strategic move for Cryoport in the cell therapy supply chain. This development addresses critical challenges in cell therapy manufacturing:
- Standardization of cryopreservation processes, which is important for maintaining cell viability and efficacy
- Integration of bioprocessing with logistics, potentially reducing time-to-patient and improving treatment outcomes
- Enhanced flexibility for therapy developers, which could accelerate clinical trials and commercialization timelines
The timing of this launch is significant, coinciding with the AABB Annual Meeting, which could provide immediate exposure to key industry players. However, the true test will be in the adoption rate by researchers and manufacturers. If successful, this platform could become an industry standard, solidifying Cryoport's position in the cell therapy ecosystem. Investors should watch for partnerships or contracts with leading cell therapy developers as indicators of market acceptance and potential future growth.
The IntegriCell Platform Will Deliver High-Quality Cryopreservation Services for Cell-Based Therapies
IntegriCell is a standardized bioprocessing, cryopreservation, and distribution solution for the global cell therapy market. The platform is designed to enhance cell therapy manufacturing efficiency and flexibility, ensuring safety, quality and product stability to support the production of these lifesaving treatments. The Cryoport Systems'
"Our new facility expands our presence on our
The Cryoport Global Supply Chain Center campus in
About Cryoport, Inc.
Cryoport, Inc. (Nasdaq: CYRX), is a global leader in supply chain solutions for the Life Sciences with an emphasis on cell & gene therapies. Cryoport enables manufacturers, contract manufacturers (CDMO's), contract research organizations (CRO's), developers, and researchers to carry out their respective business with products and services that are designed to derisk services and provide certainty. We provide a broad array of supply chain solutions for the life sciences industry. Through our platform of critical products and solutions including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, we are "Enabling the Future of Medicine™" worldwide, through our innovative systems, compliant procedures, and agile approach to superior supply chain management.
Our corporate headquarters, located in
For more information, visit www.cryoportinc.com or follow via LinkedIn at https://www.linkedin.com/company/cryoportinc or @cryoport on X, formerly known as Twitter at www.twitter.com/cryoport for live updates.
Forward-Looking Statements
Statements in this press release which are not purely historical, including statements regarding Cryoport's intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, those related to Cryoport's expectations about future benefits of the IntegriCell platform to support the development and commercialization of cell and gene therapies, including the potential impact on future revenue and revenue streams. It is important to note that Cryoport's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic and geopolitical conditions, supply chain constraints, inflationary pressures, the effects of foreign currency fluctuations, trends in the products markets, variations in Cryoport's cash flow, market acceptance risks, and technical development risks. Cryoport's business could be affected by other factors discussed in Cryoport's SEC reports, including in the "Risk Factors" section of its most recently filed periodic reports on Form 10-K and Form 10-Q, as well as in its subsequent filings with the SEC. The forward-looking statements contained in this press release speak only as of the date hereof and Cryoport cautions investors not to place undue reliance on these forward-looking statements. Except as required by law, Cryoport disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
View original content to download multimedia:https://www.prnewswire.com/news-releases/cryoport-launches-its-integricell-cryopreservation-solution-with-opening-of-new-facility-at-its-houston-campus-302268614.html
SOURCE Cryoport, Inc.
FAQ
What is Cryoport's IntegriCell™ cryopreservation solution?
Where is Cryoport's new IntegriCell™ facility located?
When is the Grand Opening event for Cryoport's new Houston facility?
What services does Cryoport's Houston campus offer?
